Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Long-term follow-up results of nonremission relapsed/refractory DLBCL with CAR T-cell cocktail therapy alone or in combination with ASCT

View Full Paper
Ask AI
Bookmark
Share

Authors

XZXiaoying ZhangJWJue WangNWNa Wang

Discussion

Loading...

Member takes

Overview

Single-arm trials reveal CAR T-cell therapy with ASCT improves clinical outcomes in relapsed DLBCL, suggesting enhanced survival benefits.

Key Points

  • Enhanced therapeutic outcomes were observed with ASCT plus CAR-T therapy compared to CAR-T alone.
  • CAR-T therapy combined with ASCT led to a higher overall response rate of 84.48%, indicating significant efficacy.
  • Analysis using propensity score matching and inverse probability treatment weighting controlled for confounders.
  • ASCT combined with CAR-T therapy shows promise for improved long-term survival and favorable safety profiles in patients.

Cite This Study

Zhang et al. (2025) studied this question.

synapsesocial.com/papers/69362f514fa91c937236d925https://doi.org/10.1182/blood-2025-7243
View Full Paper
Ask AI
Bookmark
Share